Share of global RNA therapy pipeline Q3 2023, by phase
As of 3rd quarter of 2023, 75 percent of RNAi (ribonucleic acid interference) therapies in the pipeline were still in the preclinical phase. RNA therapies, especially mRNA (messenger RNA) became well-known through the COVID-19 vaccines from Pfizer/BioNTech and from Moderna.